The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2022 | The management of DLBCL and the importance of characterizing molecular subtypes
Gerardo Musuraca, MD, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola, Italy, discusses the management of diffuse large B-cell lymphoma (DLBCL), highlighting the role of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) chemotherapy. Dr Musuraca further evaluates the importance of investigating new combination approaches to treat various molecular subtypes of DLBCL. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
